Gleevec
Term · Oncology and biomedicine · MLC-T-ONC-003562
A drug used to treat certain types of leukemia and other blood cancers, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a certain type of a rare condition called systemic mastocytosis. It is also being studied in the treatment of other conditions and types of cancer. Gleevec blocks certain proteins made by the BCR::ABL1, PDGFR, or c-KIT oncogene, which may help keep cancer cells from growing and may kill them. Gleevec is a type of tyrosine kinase inhibitor. Also called imatinib mesylate, Imkeldi, and STI571.
| Identifier | MLC-T-ONC-003562 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | imatinib mesylate; Imkeldi; STI571 |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-003562",
"term": "Gleevec",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat certain types of leukemia and other blood cancers, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a certain type of a rare condition called systemic mastocytosis. It is also being studied in the treatment of other conditions and types of cancer. Gleevec blocks certain proteins made by the BCR::ABL1, PDGFR, or c-KIT oncogene, which may help keep cancer cells from growing and may kill them. Gleevec is a type of tyrosine kinase inhibitor. Also called imatinib mesylate, Imkeldi, and STI571.",
"synonyms": [
"imatinib mesylate",
"Imkeldi",
"STI571"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/gleevec/"
}
Record 8,006 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.